Indivior Pharmaceuticals (INDV) FY2025 10-K Risk Factors: 18 New, 23 Dropped

What the changes say

Indivior restructured operations, incurring $127 million in exit costs while centralizing international focus on Australia, Canada, France, and Germany.

What changed since the prior 10-K

New

NewRisks Related to our Company and Its Business
We rely heavily on SUBLOCADE for a significant portion of our revenues
SUBLOCADE represented 69% of net revenues in 2025, while oral buprenorphine products face declining sales and severe marketing restrictions.
NewRisks Related to our Company and Its Business
Any cuts in Medicaid may impair access to our products in the U.S., thereby adversely affecting our revenues and results of operations
Generic or branded competitors targeting SUBLOCADE and SUBOXONE Film could materially reduce commercial opportunities.
NewRisks Related to our Company and Its Business
As a result of the above factors, any failure to retain key personnel or attract new personnel could have a material adverse effect on our business, prospects, results of operations and financial condition
The U.S. federal Anti-Kickback Statute and other fraud and abuse laws create high compliance scrutiny for sales, marketing, and patient support.
NewRisks Related to our Company and Its Business
whistleblower lawsuits, under the False Claims Act. Compliance with these laws, including the development of a comprehensive compliance program, is difficult, costly and time-consuming
Global anti-bribery and corruption laws carry severe penalties, including fines, criminal sanctions, and exclusion from government healthcare programs.
NewRisks Related to our Company and Its Business
We have made various changes to our business and announced estimated exit costs related to those changes, but our estimates of those costs may differ materially from our estimates
Restructuring in 2025 included discontinuing OPVEE nasal spray and halting Rest of World operations in the U.K., Ireland, Sweden, Israel, Finland, and Italy, incurring $127 million in exit costs.
NewRisks Related to our Company and Its Business
same time they reflect increased value of products or potential products as development or sales milestones are attained
Reliance on contract research organizations and collaboration partners creates risks of disputes, IP loss, and delayed clinical trials.
NewRisks Related to our Company and Its Business
For example, in September 2024, following a Phase II clinical trial that failed to meet its primary endpoint, we made the decision to not exercise our option for AEF0117, a synthetic CB1-specific signaling inhibitor, which we had acquired in June 2021 from the French company Aelis Farma
The September 2024 termination of the AEF0117 option followed a Phase II clinical trial failure to meet its primary endpoint.
NewRisks Related to our Company and Its Business
while we can set certain contractual expectations, we may be unable to control the amount and timing of resources that the clinical sites and third parties may devote to our clinical trials
Clinical trial delays can occur if third-party investigators and clinical sites fail to enroll enough qualified patients or comply with GCPs.
NewRisks Related to Regulatory or Legal Matters
consequences of non-compliance with any of the post-approval obligations described above could have an adverse impact on its business, prospects, results of operations and financial condition
Controlled substance designation by the DEA for products like INDV-6001 may be restrictive and delay commercialization.
NewRisks Related to Regulatory or Legal Matters
Collectively, existing and future healthcare regulatory and legislative developments could increase compliance costs, limit pricing or reimbursement flexibility, reduce patient access, or otherwise materially adversely affect our business, prospects, and results of operations
Healthcare regulatory and legislative developments like the rebate rule and the Inflation Reduction Act create drug pricing uncertainty.
NewRisks Related to Regulatory or Legal Matters
between pharmacy benefit managers and manufacturers. The Inflation Reduction Act subsequently extended the moratorium on implementation, administration, or enforcement of this final rule until January 1, 2032
The Inflation Reduction Act mandates Medicare drug price negotiations and inflation-based penalties on certain Part B and Part D drugs.
NewRisks Related to Regulatory or Legal Matters
communities. Recommendations by government agencies or other groups and organizations may relate to such matters as usage, dosage, route of administration and use of related therapies
Value assessments by private and government health technology organizations increasingly influence drug reimbursement decisions.
NewRisks Related to our Financial Condition and Tax Matters
Our balance sheet is leveraged, and any reduction in revenue or change in our estimates may adversely affect our liquidity and profitability
NewRisks Related to our Financial Condition and Tax Matters
Weakness in the economy, geopolitics, market trends, disruptions in our supply chain, uncertainty, and other conditions in the markets in which we operate, particularly in the U.S., may adversely affect our sales growth and results of operations
NewRisks Related to Our Common Stock
movements. Any or all of these factors could result in material fluctuations in the price of our common stock, which could result in investors getting back less than they invested or a total loss of their investment
NewRisks Related to Our Common Stock
Purchase Agreement. Any return to stockholders therefore likely will be limited to the increase in the price of our common stock, if any
NewRisks Related to Our Common Stock
We are subject to anti-takeover provisions in our certificate of incorporation and bylaws and under Delaware law that could delay or prevent an acquisition of our company, even if the acquisition would be beneficial to our stockholders
NewRisks Related to Information Security and Data Privacy
Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data

Dropped

DroppedRisks Related to our Company and Its Business
particular period. In addition, negative publicity related to these proceedings may negatively impact the Company’s reputation
DroppedRisks Related to our Company and Its Business
custody, restricted supply of raw materials or components due to geopolitical disruption or pandemic, and environmental factors
Civil opioid litigation and dental allegations disclosures.
DroppedRisks Related to our Company and Its Business
Our success will also depend in large part on our ability to continue to successfully manufacture and commercialize new products in the complex markets into which they are sold
DroppedRisks Related to our Company and Its Business
Any factors preventing or limiting the market acceptance or commercialization of our products could cause us to recognize charges as we did with PERSERIS and could have a material adverse effect on their sales and hence our business, results of operations and financial condition
DroppedRisks Related to our Company and Its Business
Reimbursement guidelines and incentives provided to prescribing physicians by third party payors may have a significant impact on the prescribing physicians’ willingness and ability to prescribe our products
DroppedRisks Related to our Company and Its Business
products as an alternative to branded products, and/or branded products available through parallel import to keep healthcare costs down
DroppedRisks Related to our Company and Its Business
to comply with these regulations may require us to repeat or redesign clinical trials, which would delay the regulatory approval process or expose us to regulatory sanctions
Manufacturing facility labor costs and supply chain disruptions.
DroppedRisks Related to our Company and Its Business
We face additional risks as a manufacturer that manufactures pharmaceutical products for others and, in the future, for ourselves
Commercialization history of SUBLOCADE and competitor entry.
DroppedRisks Related to our Company and Its Business
as depreciation of excess capacity, incremental compensation expense from additional headcount, and incremental information technology and other expenses, resulting in expected operating losses for the Raleigh Manufacturing Facility
PERSERIS charges and third-party reimbursement constraints.
DroppedRisks Related to our Company and Its Business
If we fail to develop or acquire other new products or compounds for development, our business, prospects, results of operations and financial condition could be materially adversely affected
Physician reimbursement incentives impacting prescribing habits.
DroppedRisks Related to our Company and Its Business
See “Item 1.Business —Pipeline,” for more information
European government-sponsored healthcare systems reducing drug expenditures.
DroppedRisks Related to Intellectual Property
We may not be able to protect our intellectual property rights throughout the world which could have an adverse effect on our business, results of operations and financial condition
DroppedRisks Related to Intellectual Property
We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers
DroppedRisks Related to Regulatory or Legal Matters
Any of the foregoing could have a material adverse effect on our business, prospects, results of operations and financial condition
Clinical trial non-compliance requiring trial repeats or redesign.
DroppedRisks Related to our Financial Condition and Tax Matters
We have limited capacity to raise prices to recover costs of tariffs because, for example, the federal Inflation Reduction Act limits US pharma price increases to no greater than a certain inflation rate, and increases in excess of inflation trigger a 100% excise tax
DroppedRisks Related to our Financial Condition and Tax Matters
Our balance sheet is leveraged, and any reduction in annual sales may adversely affect our liquidity
DroppedRisks Related to our Financial Condition and Tax Matters
We may not be able to generate sufficient cash to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness
Raleigh Manufacturing Facility third-party production obligations.
DroppedRisks Related to Our Ordinary Shares
Our ordinary shares are listed to trade on more than one stock exchange, and this may result in price variations
Capital equipment investments for aseptic syringe filling at Raleigh.
DroppedRisks Related to Our Ordinary Shares
We face a number of risks associated resulting from the relocation of our primary listing
Strategy of acquiring new products through business development.
DroppedRisks Related to Our International Status and Operations
We are subject to various risks related to the local and international nature of our business, including domestic and foreign laws, regulations, and standards. Failure to comply with such laws and regulations or the occurrence of unforeseen developments such as litigation could adversely affect our business
Technical and financial resource requirements for product acquisitions.
DroppedRisks Related to Our International Status and Operations
our exposure to exchange rate fluctuations, our business, financial condition, and results of operations could be materially adversely affected
DroppedRisks Related to Being a Publicly-Traded Company in the U.S
The determination of foreign private issuer status is made annually on the last business day of an issuer’s most recently completed second financial quarter. Accordingly, we will next make a determination with respect to our foreign private issuer status on June 30, 2025
DroppedRisks Related to Being a Publicly-Traded Company in the U.S
We have changed the financial reporting standards that we apply to our financial statements from IFRS to U.S. GAAP and, as a result, some of our financial data may not be easily comparable to historical financial results

Reworded

98% rewrittenRisks Related to our Company and Its Business
We may be subject to adverse public opinion
Updated to explicitly state that negative public opinion regarding opioid-based medications for OUD could damage reputation and limit product acceptance.
96% rewrittenRisks Related to our Company and Its Business
Congressional action to reduce spending may result in cuts to Medicaid which in turn might impair access to our products in the U.S., thereby adversely affecting our revenues and results of operations
Added specific reference to the 2025 budget reconciliation act (OBBBA) and potential Medicaid work or eligibility requirements.
95% rewrittenRisks Related to Regulatory or Legal Matters
We are subject to federal, state and foreign healthcare laws and regulations and implementation or changes to such healthcare laws and regulations could adversely affect our business and results of operations
Clarified global regulatory scope across the United States, the European Union, and other jurisdictions.
94% rewrittenRisks Related to our Financial Condition and Tax Matters
Tariffs on pharmaceutical products, and potential reciprocal responses by other countries, may adversely affect our revenues or profitability
Added details regarding API imports from the U.K. currently exempt from tariffs for 3 years under a U.S./U.K. agreement, alongside potential export risks to Canada and Australia.
Was: Recently proposed tariffs on pharmaceutical products, and potential reciprocal responses by other countries, may adversely affect our revenues or profitability
88% rewrittenRisks Related to Regulatory or Legal Matters
Guidelines and coverage determinations published by the government, professional societies, insurance carriers, physician groups, science foundations, and other organizations may affect the use of the Company’s products
Truncated the closing sentence regarding patient communities in guidelines and coverage determinations.
87% rewrittenRisks Related to Our Common Stock
Provisions of our Note Purchase Agreement may deter or prevent an otherwise beneficial takeover attempt of us
Updated Note Purchase Agreement change of control definitions from Indivior PLC to Indivior Pharmaceutical.
Was: Provisions of our Note Purchase Agreement and the U.K. City Code on Takeovers and Mergers may deter or prevent an otherwise beneficial takeover attempt of us
85% rewrittenRisks Related to our Company and Its Business
Our revenues may grow at a slower than expected rate or decrease due to many factors
Added patient and physician satisfaction and generic competition changes to revenue growth risk factors.
83% rewrittenRisks Related to Being a Publicly-Traded Company in the U.S
Changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters, could significantly affect our financial results or financial condition
Minor stylistic and phrasing adjustments to accounting standards and subjective assumptions disclosures.
81% rewrittenRisks Related to our Company and Its Business
We rely on third parties to manufacture, package, test, and distribute our products and their facilities and processes must meet stringent regulatory requirements
77% rewrittenRisks Related to our Company and Its Business
The clinical study or commercial use of our products may cause unintended side effects or adverse reactions, or incidents of misuse may occur, which could adversely affect our products, business and share price
77% rewrittenRisks Related to our Company and Its Business
Most of our pharmaceutical pipeline relies on collaborations with third parties, which may adversely affect the development and sale of our products
76% rewrittenRisks Related to our Financial Condition and Tax Matters
Our deferred tax assets may not be realized
75% rewrittenRisks Related to our Company and Its Business
We are subject to risks related to the manufacture and distribution of our products globally and must meet stringent current Good Manufacturing Practices
65% rewrittenRisks Related to our Company and Its Business
Acquisitions, partnerships, joint ventures, dispositions, and other business combinations or strategic transactions involve several inherent risks, any of which could result in the benefits anticipated not being realized and could have an adverse effect on our business, financial condition, and results of operations
65% rewrittenRisks Related to Regulatory or Legal Matters
The pharmaceutical sector is facing increased government scrutiny from competition and pricing authorities around the world, and any failure to comply, may expose us to significant damages and commercial restrictions that can materially and adversely affect our business
61% rewrittenRisks Related to our Company and Its Business
We are currently, in the past have been, and in the future may be, subject to substantial litigation that could cause us to incur significant legal expenses, divert management’s attention, and result in harm to our business
60% rewrittenRisks Related to Our International Status and Operations
We are exposed to risks related to currency exchange rates
54% rewrittenRisks Related to our Company and Its Business
Clinical trials for the development of products, including our key pipeline products, may be unsuccessful and our product candidates may not receive authorization for manufacture and sale
54% rewrittenRisks Related to our Company and Its Business
may be particularly vigilant in our markets because we serve at-risk populations and because we already market several products in the space
Was: In the future, our ability to acquire additional companies or products synergistic with our current businesses may be limited by antitrust regulators who may be particularly vigilant in our markets because we serve at-risk populations and because we already market several products in the space
52% rewrittenRisks Related to Our Common Stock
Our common stock is subject to market price volatility and the market price may decline disproportionately in response to developments that are unrelated to our operating performance
Was: Our ordinary shares are subject to market price volatility and the market price may decline disproportionately in response to developments that are unrelated to our operating performance
50% rewrittenRisks Related to Our Common Stock
The Parent Company is a holding company with no business operations of its own and depends on its subsidiaries for cash, including in order to pay dividends or repurchase shares
Was: The Parent Company is a holding company with no business operations of its own and depends on its subsidiaries for cash, including in order to pay dividends or make share repurchases
46% rewrittenRisks Related to our Company and Its Business
Failure to retain key personnel or attract new personnel could have a material adverse effect on us
37% rewrittenRisks Related to Our Common Stock
If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
Was: If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline
37% rewrittenRisks Related to Regulatory or Legal Matters
The FDA, the DEA, or other regulatory agencies may impose limitations or post-approval requirements on approvals for our products
32% rewrittenRisks Related to Our Common Stock
We may not pay dividends or repurchase our shares in the future. Our ability to pay dividends, repurchase our shares, or make other returns of capital in the future depends, among other things, on our financial performance
30% rewrittenRisks Related to our Financial Condition and Tax Matters
Our insurance coverage may not be adequate
28% rewrittenRisks Related to our Financial Condition and Tax Matters
Our effective tax rate may increase, and changes in tax rules and regulations, or interpretations thereof, may adversely affect our financial condition
24% rewrittenRisks Related to our Financial Condition and Tax Matters
Our operating results may fluctuate significantly
23% rewrittenRisks Related to Regulatory or Legal Matters
Product liability and product recalls could have a material adverse effect on us

All 59 risk factors

Headings as the filing states them, in filing order.

Risks Related to our Company and Its Business

01We are subject to risks related to the manufacture and distribution of our products globally and must meet stringent current Good Manufacturing Practices75% rewritten
02We rely heavily on SUBLOCADE for a significant portion of our revenuesNew
03Our revenues may grow at a slower than expected rate or decrease due to many factors85% rewritten
04We rely on third parties to manufacture, package, test, and distribute our products and their facilities and processes must meet stringent regulatory requirements81% rewritten
05We are currently, in the past have been, and in the future may be, subject to substantial litigation that could cause us to incur significant legal expenses, divert management’s attention, and result in harm to our business61% rewritten
06We are subject to additional risks because we import, manufacture, and distribute controlled substances
07Acquisitions, partnerships, joint ventures, dispositions, and other business combinations or strategic transactions involve several inherent risks, any of which could result in the benefits anticipated not being realized and could have an adverse effect on our business, financial condition, and results of operations65% rewritten
08may be particularly vigilant in our markets because we serve at-risk populations and because we already market several products in the space54% rewritten
09The clinical study or commercial use of our products may cause unintended side effects or adverse reactions, or incidents of misuse may occur, which could adversely affect our products, business and share price77% rewritten
10Congressional action to reduce spending may result in cuts to Medicaid which in turn might impair access to our products in the U.S., thereby adversely affecting our revenues and results of operations96% rewritten
11Any cuts in Medicaid may impair access to our products in the U.S., thereby adversely affecting our revenues and results of operationsNew
12Failure to retain key personnel or attract new personnel could have a material adverse effect on us46% rewritten
13As a result of the above factors, any failure to retain key personnel or attract new personnel could have a material adverse effect on our business, prospects, results of operations and financial conditionNew
14whistleblower lawsuits, under the False Claims Act. Compliance with these laws, including the development of a comprehensive compliance program, is difficult, costly and time-consumingNew
15We may be subject to adverse public opinion98% rewritten
16We use hazardous materials in our manufacturing facilities, and any claims relating to the improper handling, storage, release or disposal of these materials could be time-consuming and expensive
17We have made various changes to our business and announced estimated exit costs related to those changes, but our estimates of those costs may differ materially from our estimatesNew
18Most of our pharmaceutical pipeline relies on collaborations with third parties, which may adversely affect the development and sale of our products77% rewritten
19same time they reflect increased value of products or potential products as development or sales milestones are attainedNew
20Clinical trials for the development of products, including our key pipeline products, may be unsuccessful and our product candidates may not receive authorization for manufacture and sale54% rewritten
21For example, in September 2024, following a Phase II clinical trial that failed to meet its primary endpoint, we made the decision to not exercise our option for AEF0117, a synthetic CB1-specific signaling inhibitor, which we had acquired in June 2021 from the French company Aelis FarmaNew
22while we can set certain contractual expectations, we may be unable to control the amount and timing of resources that the clinical sites and third parties may devote to our clinical trialsNew

Risks Related to Intellectual Property

23Failure to obtain and maintain patents and protect other proprietary rights, including in-licenses of such rights from third parties, may adversely affect us
24We may incur substantial costs as a result of litigation or other proceedings relating to patents and other intellectual property rights, and we may be unable to protect our rights to, or commercialize our products

Risks Related to Regulatory or Legal Matters

25The FDA, the DEA, or other regulatory agencies may impose limitations or post-approval requirements on approvals for our products37% rewritten
26consequences of non-compliance with any of the post-approval obligations described above could have an adverse impact on its business, prospects, results of operations and financial conditionNew
27We are subject to ongoing obligations and continued regulatory inspection by the FDA and equivalent foreign regulatory agencies, and we may be subject to penalties and litigation and large incremental expenses if we fail to comply with regulatory requirements or experience problems with our products
28The regulations, policies or guidance of regulatory agencies may change, and new or additional statutes or government regulations may be enacted that could prevent or delay regulatory approval of our product candidates or further restrict or regulate post-approval activities
29Product liability and product recalls could have a material adverse effect on us23% rewritten
30We are subject to federal, state and foreign healthcare laws and regulations and implementation or changes to such healthcare laws and regulations could adversely affect our business and results of operations95% rewritten
31Collectively, existing and future healthcare regulatory and legislative developments could increase compliance costs, limit pricing or reimbursement flexibility, reduce patient access, or otherwise materially adversely affect our business, prospects, and results of operationsNew
32between pharmacy benefit managers and manufacturers. The Inflation Reduction Act subsequently extended the moratorium on implementation, administration, or enforcement of this final rule until January 1, 2032New
33Guidelines and coverage determinations published by the government, professional societies, insurance carriers, physician groups, science foundations, and other organizations may affect the use of the Company’s products88% rewritten
34communities. Recommendations by government agencies or other groups and organizations may relate to such matters as usage, dosage, route of administration and use of related therapiesNew
35Failure to comply with payment and reporting obligations under the Medicaid Drug Rebate program or other governmental pricing programs in the U.S. could result in additional reimbursement requirements, penalties, sanctions and fines
36Failure to comply with anti-corruption laws and regulations, anti-money laundering laws and regulations, and/or economic sanctions could result in us becoming subject to fines or penalties
37The pharmaceutical sector is facing increased government scrutiny from competition and pricing authorities around the world, and any failure to comply, may expose us to significant damages and commercial restrictions that can materially and adversely affect our business65% rewritten

Risks Related to our Financial Condition and Tax Matters

38Our balance sheet is leveraged, and any reduction in revenue or change in our estimates may adversely affect our liquidity and profitabilityNew
39Our effective tax rate may increase, and changes in tax rules and regulations, or interpretations thereof, may adversely affect our financial condition28% rewritten
40Our deferred tax assets may not be realized76% rewritten
41Tariffs on pharmaceutical products, and potential reciprocal responses by other countries, may adversely affect our revenues or profitability94% rewritten
42Weakness in the economy, geopolitics, market trends, disruptions in our supply chain, uncertainty, and other conditions in the markets in which we operate, particularly in the U.S., may adversely affect our sales growth and results of operationsNew
43Our operating results may fluctuate significantly24% rewritten
44Any future pandemic, and governmental and societal responses thereto, may harm our business, results of operations, and financial condition
45Our insurance coverage may not be adequate30% rewritten
46Our term loan contains certain covenants that could limit our ability to plan for or respond to changes in our business

Risks Related to Our Common Stock

47Our common stock is subject to market price volatility and the market price may decline disproportionately in response to developments that are unrelated to our operating performance52% rewritten
48movements. Any or all of these factors could result in material fluctuations in the price of our common stock, which could result in investors getting back less than they invested or a total loss of their investmentNew
49If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline37% rewritten
50The Parent Company is a holding company with no business operations of its own and depends on its subsidiaries for cash, including in order to pay dividends or repurchase shares50% rewritten
51We may not pay dividends or repurchase our shares in the future. Our ability to pay dividends, repurchase our shares, or make other returns of capital in the future depends, among other things, on our financial performance32% rewritten
52Purchase Agreement. Any return to stockholders therefore likely will be limited to the increase in the price of our common stock, if anyNew
53We are subject to anti-takeover provisions in our certificate of incorporation and bylaws and under Delaware law that could delay or prevent an acquisition of our company, even if the acquisition would be beneficial to our stockholdersNew
54Provisions of our Note Purchase Agreement may deter or prevent an otherwise beneficial takeover attempt of us87% rewritten

Risks Related to Information Security and Data Privacy

55Business interruptions or breaches of data security could disrupt our product sales and delay the development of our product candidates
56We rely on systems, networks, products, and services, some of which are managed by third-party service providers to protect our information. Increased information security threats, more sophisticated cyber-attacks and a growing base of diversified threat actors continually pose a risk to all systems and data
57Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal dataNew

Risks Related to Our International Status and Operations

58We are exposed to risks related to currency exchange rates60% rewritten

Risks Related to Being a Publicly-Traded Company in the U.S

59Changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters, could significantly affect our financial results or financial condition83% rewritten

Other Indivior Pharmaceuticals 10-Ks

FY2024 10-K risk factors
64 risks
Indivior faces heavy litigation, reliance on third-party manufacturers, and regulatory scrutiny over controlled substances like buprenorphine. The business is exposed to pricing pressures, potential Medicaid cuts, and international tariff proposals on pharmaceuticals.
Filed Mar 03, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.